Oramed Pharmaceuticals Inc.
NASDAQ:ORMPBiotechnology
+$0.03 today
- Market cap
- $169.16M
- Beta
- 1.24
- P/E (TTM)
- 1.4
- EPS (TTM)
- $2.70
- Dividend yield
- 6.54%
Volume 0.16M
Average 0.16M
ORMP Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Oramed Pharmaceuticals Inc.NASDAQ: ORMP
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures grows, but more slowly than its trailing trend
Q1 FY2026 capital expenditures of $5K (cash outflow) rose 66.7% year over year, behind the +1114.8% change in trailing-twelve-month capital expenditures. Over 3 fiscal years it compounded at +57.4% a year.
Context
- Capital expenditures amounted to 96.7% of revenue in FY2025.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +66.7% toward the trailing-twelve-month pace of +1114.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (1.93M) USD
- Year-over-year change
- -10639.5%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.93M) | -10639.5% |
| FY2024 | 2024-12-31 | (18K) | +92.9% |
| FY2023 | 2023-12-31 | (254K) | +48.8% |
| FY2022 | 2022-12-31 | (496K) | -32.3% |
| FY2021 | 2021-08-31 | (375K) | — |
Capital Expenditures vs competitors
How ORMP compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +1114.8% is the highest of 8, against a peer median of -9.7%.
- Over three fiscal years its annual growth of +57.4% compares with a peer median of -56.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $10.42M USD | -12.9% | -81.7% | 1042.3% | |
| LTM Mar 2026 | $1.73M USD | -37.7% | -19.2% | 1.1% | |
| FY2025 | $434K USD | -42.1% | -53.4% | 678.1% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $200K USD | — | — | — |
| LTM Mar 2026 | $192.68K USD | +1114.8% | +57.4% | — | |
| LTM Mar 2026 | €114.87K EUR | +178.5% | -11.9% | 391.6% | |
| LTM Mar 2026 | $39K USD | +874.9% | -80.4% | 29.1% | |
| LTM Mar 2026 | $37.26K USD | -9.7% | -60.2% | — | |
| LTM Mar 2026 | $3 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | +100.0% | — | 0.0% | |
IMAImageneBio Inc | LTM Mar 2026 | $0 USD | — | — | — |
| Peer median (excluding ORMP) | — | -9.7% | -56.8% | 29.1% | |
Competitors are the stored peer set for ORMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Aug 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (22.24M) | (36.56M) | 5.53M | (19.06M) | 64.02M |
| Depreciation & Amortization | 77K | 58K | 196K | 193K | 121K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 7.91M |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 5.99M |
| Change in Working Capital | (1.32M) | (943K) | (2.7M) | 3.2M | (1.91M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.06M | (376K) | (2.23M) | 3.53M | 1.13M |
| Other Working Capital | (3.38M) | (567K) | (471K) | (325K) | (3.04M) |
| Other Non-Cash Items | 2.3M | 8.75M | (13.32M) | 7.26M | (85.28M) |
| Operating Cash Flow | (21.18M) | (28.7M) | (10.3M) | (8.41M) | (9.15M) |
| Capital Expenditures | (375K) | (496K) | (254K) | (18K) | (1.93M) |
| Acquisitions (Net) | 1.5M | 24K | 0 | 0 | (7.25M) |
| Purchases of Investments | (53.82M) | (154.41M) | (190.92M) | (55.76M) | (88.51M) |
| Sales of Investments | 30.43M | 185.09M | 118.14M | 161.65M | 96.88M |
| Other Investing Activities | (1K) | 2K | 0 | (60K) | 6.25M |
| Investing Cash Flow | (22.26M) | 30.21M | (73.04M) | 105.82M | 5.44M |
| Debt Repayment | — | — | 49.55M | (49.55M) | 0 |
| Common Stock Issued | 101.39M | 11.56M | 2.43M | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | (2.48M) | (4.74M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | (2K) | 0 |
| Financing Cash Flow | 101.39M | 11.56M | 51.98M | (52.04M) | (4.74M) |
| Effect of Forex Changes | 2K | (49.85M) | (54K) | (4K) | (30K) |
| Net Change in Cash | 57.95M | (36.78M) | (31.41M) | 45.37M | (8.47M) |
| Free Cash Flow | (21.56M) | (29.2M) | (10.55M) | (8.43M) | (11.08M) |
Oramed Pharmaceuticals Inc.
NASDAQ:ORMP
Intrinsic Alpha fair value
Locked
Current Price
$3.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.